Emapalumab (anti-IFNγ)

Catalog No.A2041 Synonyms: Gamifant

For research use only.
Not for use in humans.

Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.

Emapalumab (anti-IFNγ)

Purity & Quality Control

Choose Selective IFN Inhibitors

Biological Activity

Description Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.

Protocol (from reference)

Product Details

CAS No. 1709815-23-5
Molecular Weight 135 KD
Formulation PBS Buffer, PH 7.4
Isotype Human IgG1
Application Emapalumab (anti-IFNγ)
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
Sterility 0.2 μM filtered

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Emapalumab (anti-IFNγ) | Emapalumab (anti-IFNγ) supplier | purchase Emapalumab (anti-IFNγ) | Emapalumab (anti-IFNγ) cost | Emapalumab (anti-IFNγ) manufacturer | order Emapalumab (anti-IFNγ) | Emapalumab (anti-IFNγ) distributor